What is Aileron Therapeutics Price-to-Tangible-Book?
As of today (2024-04-25), Aileron Therapeutics's share price is $4.93. Aileron Therapeutics's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $-16.10. Hence, Aileron Therapeutics's Price to Tangible Book Ratio of today is .
The historical rank and industry rank for Aileron Therapeutics's Price-to-Tangible-Book or its related term are showing as below:
During the past 9 years, Aileron Therapeutics's highest Price to Tangible Book Ratio was 3.75. The lowest was 0.58. And the median was 1.08.
ALRN's Price-to-Tangible-Book is not ranked *
in the Biotechnology industry.
Industry Median: 2.69 * Ranked among companies with meaningful Price-to-Tangible-Book only.
A closely related ratio is called PB Ratio. As of today, Aileron Therapeutics's share price is $4.93. Aileron Therapeutics's Book Value per Sharefor the quarter that ended in Dec. 2023 was $1.41. Hence, Aileron Therapeutics's P/B Ratio of today is 3.50.
Aileron Therapeutics Price-to-Tangible-Book Historical Data
The historical data trend for Aileron Therapeutics's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Aileron Therapeutics's Price-to-Tangible-Book
For the Biotechnology subindustry, Aileron Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aileron Therapeutics's Price-to-Tangible-Book Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aileron Therapeutics's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Aileron Therapeutics's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Aileron Therapeutics Price-to-Tangible-Book Related Terms
Thank you for viewing the detailed overview of Aileron Therapeutics's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.
Aileron Therapeutics (Aileron Therapeutics) Business Description
Aileron Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing a novel class of therapeutics for the treatment of cancer and other diseases. The company's lead product candidate, ALRN-6924 is a novel chemoprotective medicine to treat and protect healthy cells in patients with cancer that harbors p53 mutations to reduce or eliminate chemotherapy-induced side effects.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ALRN has been successfully added to your 